Bio News
Apnimed raised $192 million in an IPO to prepare for the launch of the sleep apnea treatment AD109. The company offered 12 million shares at $16 per share and could receive up to an additional $28.8 million if underwriters exercise their option. In a phase 3 trial involving 660 participants, AD109 reduced apnea events by 46.8%, and the FDA is expected to decide whether to approve it by February 2027.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
